Key Highlights
- OMDA shares traded up 6.36% to $19.21, versus a prior close of $18.06.
- Care Track members lost 6.0% of starting body weight in 12 weeks, versus 3.3% for usual care.
- Body fat percentage fell about twice as much, by 3.3% versus 1.6%.
- The study followed 245 adults who had recently started a GLP-1.
- Second-quarter revenue rose 43% to $88 million.
GLP-1 Care Track Shows Greater Weight Loss and Muscle Retention in 12-Week Study
Omada Health (NASDAQ:OMDA) shares traded up 6.36% to $19.21 after the company announced it will present peer-reviewed research at the World Obesity and Weight Management Congress in Boston. The findings were published in the journal Diabetes, Obesity and Metabolism.
The study followed 245 adults with obesity who had started a GLP-1 medication within the previous eight weeks. Of those, 151 joined Omada's GLP-1 Care Track and 94 received usual care. After 12 weeks, Care Track members lost 6.0% of starting body weight versus 3.3%, and their muscle mass percentage rose 0.6% versus 0.2%.
Members also reported greater gains in well-being and physical functioning, and saw depression and anxiety symptoms fall by roughly 30%.
Virtual Care Model Targets the Space Between Doctor Visits
San Francisco-based Omada provides virtual-first care for chronic conditions including prediabetes, diabetes, hypertension and musculoskeletal problems, using human-led care teams, connected devices and AI-enabled technology. The Care Track adds a health coach, peer support groups, meal-logging tools and an exercise plan developed by a physical therapist.
The company has served more than two million members across 2,000-plus employers, health plans, pharmacy benefit managers and health systems. It noted that lean mass can account for 30% or more of weight lost on GLP-1 medications, which is why body composition matters.
43% Revenue Growth and a 73% Gross Margin Anchor the Story
In the second quarter, revenue rose 43% year over year to $88 million, with a 73% gross margin and $5 million in net income. Market capitalization is about $1.18 billion, and the stock trades at 60.46 times forward earnings. The 52-week range runs from $10.28 to $26.92.
Broader healthcare strength is a tailwind, with the sector ETF near a 52-week high, though volume is light against average.
Congress Presentation Keeps Attention on GLP-1 Support Programs
Omada's clinical research scientist presents the findings during the Anti-Obesity Drugs and Emerging Therapies session at the congress, which runs October 19 to 21. The company said the study suggests clinical support between doctor visits can help people achieve greater weight loss and better body composition. Investors will watch whether such evidence supports demand from employers and health plans.


_11_19_2026_08_23_11_186799.jpg)



Please wait processing your request...